Glaucoma Suspect

3

Review clinical trials related to Glaucoma Suspect. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Know Your Pressures NYC

Dr. Lisa A. Hark (PI and Study Chair) and an interdisciplinary team have designed "Know Your Pressures NYC" to conduct blood pressure (BP)/glaucoma screenings in adults age 40+ to identify undiagnosed and/or uncontrolled hypertension and/or glaucoma/suspect. For the purpose of this study, individuals will be identified as glaucoma suspects if they have elevated intraocular pressure (IOP) or have features of glaucoma optic neuropathy, as assessed by optical coherence tomography (OCT) and fundus/optic nerve photographs, as interpreted by the masked Reading Center.

Participants needed: 7,085
Trial details
Age: 40+Biological sex: AllType: InterventionalSponsor: Columbia UniversityUpdated: Aug 25, 2026Locations: 1
Eligibility criteria

Individuals age 40 and older. [+2]

Self-reported terminal illness with life expectancy less than 1 year. [+1]

Status: Recruiting

Automated Applanation Tonometry - Updated

Goldmann Applanation Tonometry (GAT) is considered the clinical gold standard for eye pressure measurements and yet it is known to be a subjective measurement with limited repeatability and limited portability. Another clinical standard for checking eye pressure is known as the pneumotonometer. This method is more objective but not portable. The purpose of this study is to develop new methods of measuring eye pressure that are more objective, reproducible and portable. In this study, the investigators will be comparing the eye pressure measurements using 2 investigational methods to GAT and pneuumotonometer.

Participants needed: 200
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Duke UniversityUpdated: Mar 6, 2026Locations: 1
Eligibility criteria

Presenting for a routine eye exam [+2]

History of corneal scarring [+2]

Status: Recruiting

Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use

The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.

Participants needed: 20
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: University of MiamiUpdated: Mar 5, 2026Locations: 1
Eligibility criteria

Eye with open-angle glaucoma or suspected of open-angle glaucoma [+5]

Retinal disease (e.g., wet age-related macular degeneration, proliferative diabe... [+7]